Which Safety and Efficacy Signals Should Be Tracked When Combining Cagrilintide with Semaglutide Across the 2026 Phase 3 Trial Dataset?

The 2026 phase 3 dataset for the cagrilintide plus semaglutide combination spans REDEFINE 1, REDEFINE 2, and the REIMAGINE 1 through 3 program. These trials establish five trackable signal categories: body-weight reduction versus each monotherapy arm, glycaemic control, gastrointestinal adverse-event incidence, treatment-discontinuation rates, and cardiometabolic surrogate markers. Each category has a defined comparator arm and a measurable delta.

How Does the Combination's Weight-Reduction Signal Compare to Each Monotherapy Arm?

REDEFINE 1 is the primary three-arm weight reference at 68 weeks. The combination achieved approximately 23% mean body-weight reduction versus approximately 16% for semaglutide monotherapy and approximately 12% for cagrilintide monotherapy. The incremental delta over semaglutide alone is approximately 6 to 7 percentage points.

REDEFINE 2 enrolled adults with type 2 diabetes and reported approximately 16% body-weight reduction with the combination versus approximately 10% with semaglutide alone at 68 weeks. The delta narrows to approximately 6 percentage points in the T2D-comorbid population.

This consistency across metabolic phenotypes confirms that the combination's weight advantage over its GLP-1 component is a robust signal. A protocol tracker should log the delta from each participant's personal semaglutide-monotherapy baseline, not just the absolute percentage.

The REDEFINE 1 design makes this feasible because it randomised participants to monotherapy arms before the combination arm was introduced. This provides within-trial reference values for the incremental amylin contribution to weight loss.

What Glycaemic Signals Distinguish the Combination from Semaglutide Alone?

REIMAGINE 2 is the primary glycaemic reference for this combination. The combination reduced HbA1c by approximately 1 point 9 percentage points at 68 weeks versus approximately 1 point 8 percentage points for semaglutide alone. Body-weight reduction was approximately 14% versus approximately 10% for semaglutide monotherapy.

REIMAGINE 1 enrolled injectable-naive adults with type 2 diabetes. CagriSema reduced HbA1c by approximately 2 percentage points and body weight by approximately 14% versus placebo. The adverse-event discontinuation rate was 3% in this injection-naive cohort.

That low discontinuation rate is a protocol-relevant signal. It suggests the combination's tolerability is not materially worse than semaglutide alone when titration is managed carefully.

Fasting plasma glucose is a secondary glycaemic signal worth tracking independently of HbA1c. The amylin receptor pathway through which cagrilintide operates suppresses postprandial glucagon secretion, a mechanism additive to GLP-1R-mediated insulin secretion enhancement. Trackers should capture both fasting and 2-hour postprandial glucose to isolate the amylin-specific contribution.

How Should Gastrointestinal Adverse-Event Incidence Be Tracked Across the Combination Arms?

REDEFINE 1 reported gastrointestinal adverse events in approximately 80% of CagriSema participants versus approximately 40% with placebo. Nausea occurred in 55% of the combination arm versus approximately 13% with placebo. The combination's GI burden must be benchmarked against the semaglutide-monotherapy arm to isolate the incremental risk from adding cagrilintide.

The tracker should capture GI events at three levels of granularity. These are event type (nausea, vomiting, diarrhea, constipation), severity grade (mild, moderate, or severe per CTCAE), and temporal pattern (onset week, peak week, resolution week).

Most GI events in REDEFINE were mild to moderate and occurred during dose escalation. A tracker that captures only event presence will miss the dose-phase dependency of the GI signal.

In REDEFINE 5, GI adverse events were reported in 53% of CagriSema participants versus 51% on semaglutide alone. This near-identical rate narrows the incremental GI burden substantially when both compounds are titrated on equivalent schedules. The GI delta seen in REDEFINE 1 versus placebo therefore does not translate directly to a GI delta versus semaglutide monotherapy.

Which Discontinuation-Rate Fields Carry the Most Protocol-Design Weight?

Adverse-event discontinuation rates were 6% for CagriSema versus approximately 4% for placebo in REDEFINE 1, and approximately 8% in REDEFINE 2. These figures represent a consistent 1 point 6 to 2 point 4 times multiplier over placebo. A protocol tracker must capture discontinuation reason, the week of discontinuation, and the last dose level reached before stopping.

The week-of-discontinuation field distinguishes titration-phase intolerance from steady-state intolerance. If discontinuations cluster in weeks 4 through 16, the signal maps to dose-ramp speed rather than the compound's intrinsic tolerability ceiling.

Trackers that log only a binary discontinued or completed field cannot make this distinction. The REIMAGINE 1 cohort's 3% discontinuation rate in injection-naive patients provides a lower-bound reference for comparison.

Comparing a running protocol's discontinuation trajectory against this benchmark allows early identification of outlier tolerability patterns. This comparison should be made before the participant reaches the full maintenance dose.

What Cardiometabolic Surrogate Markers Should Be Captured Alongside Weight and Glycaemia?

The REDEFINE 1 blood-pressure sub-analysis confirmed that CagriSema produced clinically meaningful systolic blood pressure reductions beyond those seen with semaglutide alone. A protocol tracker should capture systolic and diastolic BP, waist circumference, fasting lipid panel, and liver enzyme markers as the minimum cardiometabolic surrogate set.

Waist circumference deserves independent tracking because it captures visceral adiposity reduction that body-weight percentage may underrepresent. The amylin receptor pathway has documented effects on central fat distribution in preclinical models.

The REDEFINE weight-loss magnitude of approximately 23% is consistent with a visceral-predominant fat-loss pattern. A tracker that logs only total body weight will miss this distributional signal.

Lean mass preservation is an evidence void in the current REDEFINE dataset. No DEXA sub-study data have been published for CagriSema as of mid-2026. Trackers should flag lean-mass fields as unvalidated against a combination-arm reference until a dedicated sub-study reports.

Stack Blueprint: Signal-Tracking Fields for the Cagrilintide Plus Semaglutide Combination

The table below maps each trackable signal category to its primary trial source, the relevant comparator arm, the measurement instrument, and the evidence tier. Fields marked as void have no combination-arm reference data as of mid-2026 and must be extrapolated from monotherapy arms or flagged as unknown in any tracker implementation.

What Interaction Class Does the Current Evidence Support?

The cagrilintide plus semaglutide combination qualifies as Co-Administration Data across weight, glycaemia, GI tolerability, and discontinuation domains. Multiple phase 3 RCTs with active comparator arms provide direct co-administration reference values, not extrapolations. The lean-mass domain remains at Single-Compound Extrapolation pending DEXA sub-study publication.

The mechanistic basis for the combination's additive efficacy is non-overlapping receptor engagement. Cagrilintide activates amylin receptors (CALCR/RAMP1 and CALCR/RAMP3 heterodimers) in the area postrema and hypothalamus. It suppresses postprandial glucagon and slows gastric emptying via a pathway independent of GLP-1R signalling.

This receptor-level separation means the two compounds do not compete for the same binding site. Their downstream satiety and glycaemic effects are mechanistically additive rather than redundant. Protocol trackers should classify this combination at the Co-Administration Data tier for all tracked signals except lean mass.

Any tracker that defaults to a Proposed Additive Effect classification for this pairing is using an outdated evidence tier. The REDEFINE and REIMAGINE programs have moved the combination firmly into the controlled co-administration category. Tracker field definitions should reflect that evidence upgrade. What Do 2026 Primary Studies Show About GLP-1/GIP Dual Agonists Versus GLP-1 Monotherapy for Body-Weight Loss and Cardiometabolic Outcomes? Does Retatrutide's Phase 3 Evidence in 2026 Show Clinically Meaningful Weight Loss Beyond Semaglutide and Tirzepatide? What Does 2026 Research Show About Semaglutide's Role in Metabolic Medicine?